Tranxene Shortage: What Providers and Prescribers Need to Know in 2026

Clorazepate dipotassium (Tranxene) has long occupied a niche but important role in the prescriber's toolkit — particularly for patients with anxiety disorders who benefit from its long half-life, and for epilepsy management where its active metabolite, nordiazepam, provides sustained anticonvulsant activity. In 2026, patients and providers alike are contending with persistent challenges in filling clorazepate prescriptions. This article provides a clinical framework for understanding the supply situation and managing your patients through it effectively.

Current Supply Status: What the Data Shows

As of early 2026, clorazepate is not on the FDA Drug Shortage Database — a designation that requires manufacturer notification and has specific regulatory criteria. However, clinical reality for prescribers and their patients tells a different story. The US clorazepate market is approximately $25.8 million annually. Historically, manufacturing has been concentrated among a very small number of producers, with Recordati Rare Diseases Inc. holding the branded Tranxene product.

A meaningful development: in early 2026, ANI Pharmaceuticals received FDA approval for a new generic clorazepate dipotassium tablet, which should gradually expand manufacturing capacity and improve retail availability over the coming year.

Why Clorazepate Is Vulnerable to Supply Disruptions

Several structural factors make clorazepate particularly vulnerable:

Thin manufacturer base: With only a handful of manufacturers historically producing the drug, any single-facility disruption can reduce available supply significantly.

Low prescribing volume: Clorazepate is prescribed far less frequently than alprazolam, lorazepam, or clonazepam, which account for over 99% of benzodiazepine prescriptions. This makes retail investment in stocking clorazepate less attractive to pharmacy chains.

DEA Schedule IV constraints: Annual DEA manufacturing quotas, inventory tracking requirements, and distributor limits on controlled substance dispensing create structural bottlenecks that disproportionately affect low-volume drugs.

Post-pandemic supply chain fragility: API sourcing disruptions, particularly for compounds manufactured in Asia, continue to affect a range of generics including those in the benzodiazepine class.

Clinical Considerations: When to Anticipate Access Problems

Clorazepate's availability challenges are most likely to impact the following patient populations:

Patients with treatment-resistant epilepsy using clorazepate as adjunctive therapy, where abrupt changes in AED regimen carry seizure risk

Long-term anxiety patients who have been stable on clorazepate for months or years and for whom a formulary switch carries therapeutic risk

Patients in alcohol withdrawal management programs where the drug's long half-life is a deliberate therapeutic choice

Managing Patients Through a Clorazepate Access Issue

When a patient reports they cannot fill their clorazepate prescription, consider the following approach:

Assess immediate risk: Determine the patient's current supply. Patients with fewer than 7 days of clorazepate remaining and no pharmacy access are at acute risk for benzodiazepine withdrawal.

Bridge with diazepam if necessary: Diazepam shares the same primary active metabolite (desmethyldiazepam/nordiazepam) as clorazepate and is the most pharmacologically equivalent substitute. Approximate conversion: clorazepate 7.5 mg ≈ diazepam 5 mg. Always confirm dose using your benzodiazepine equivalency reference.

Send a pharmacy query to multiple pharmacies: Independent pharmacies and compounding pharmacies often have access to clorazepate when chains do not. Ask your office staff to call several local independent pharmacies before assuming the drug is regionally unavailable.

Document the situation: Document in the chart that the patient is experiencing difficulty accessing their prescribed medication and any bridging or transition plans. This is important for continuity of care and medicolegal documentation.

Formulary Substitution Options by Indication

If a planned transition away from clorazepate is appropriate, consider the following by indication:

Anxiety disorders: Diazepam (long-acting, same metabolite), lorazepam (intermediate-acting, widely available), or a transition to SSRI/SNRI therapy if appropriate for long-term management

Partial seizures (adjunctive): Clonazepam (FDA-approved for multiple seizure types, widely available, high potency — use equivalency tables carefully) or clobazam for certain epilepsy syndromes

Alcohol withdrawal: Diazepam or chlordiazepoxide (Librium) are the most established long-acting benzodiazepines for alcohol withdrawal and the most readily available alternatives

How medfinder Can Help Your Patients

Rather than having patients call pharmacy after pharmacy on their own — a significant burden for any patient but especially those in anxious or vulnerable states — consider recommending medfinder for providers. medfinder calls pharmacies in the patient's area to determine which can fill their prescription, then texts results directly to the patient. This reduces patient burden and the number of urgent callbacks to your office about unfilled prescriptions.

Key Takeaways for Prescribers

Clorazepate is not in an official FDA shortage but faces a structural "soft shortage" due to a thin manufacturer base and low pharmacy stocking rates

ANI Pharmaceuticals' new generic approval in 2026 should gradually improve supply

Never instruct patients to stop clorazepate abruptly — this can cause life-threatening seizures

Diazepam is the most pharmacologically similar substitution option when needed

Independent pharmacies are often better positioned to source clorazepate than large chain pharmacies